The Claim
Among US veterans with type 2 diabetes, initiating GLP-1 receptor agonists is associated with a 25% lower risk of developing opioid use disorder over a three-year period compared to initiating SGLT-2 inhibitors, with a net reduction of 0.86 cases per 1000 people, suggesting a potential role in opioid use prevention.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For US veterans with type 2 diabetes, taking GLP-1 drugs might help lower the chance of getting hooked on opioids over three years compared to another diabetes drug, SGLT-2 inhibitors — about 1 fewer case for every 1,000 people.
See the scientific wording
Initiating GLP-1 receptor agonists is associated with a 25% lower risk of opioid use disorder over three years compared to initiating SGLT-2 inhibitors among US veterans with type 2 diabetes, with a net reduction of 0.86 cases per 1000 people, suggesting potential utility in opioid use prevention.
What the research says
1 studyThe study found that veterans with type 2 diabetes who started GLP-1 drugs had a 25% lower risk of developing opioid use disorder over three years compared to those who started SGLT-2 drugs, and the number of prevented cases matched the claim exactly.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.